Facing a R9-billion shortfall just to meet salary demands, provincial health departments are freezing posts. Whether couched openly in memos or hidden between the lines of spiralling bureaucracy, staff freezes may be South Africa’s most significant threat to healthcare.
Following reports of shortages of 300mg lamivudine tablets, the Department of Health has assured the public there is no stock out of the antiretroviral (ARV) and issued clinician guidance regarding the formulation, which will no longer be offered on tender.
After months of erratic supply of its antiretroviral (ARV) Aluvia in South Africa, international pharmaceutical company AbbVie will now allow generic manufacturers to produce the drug to help safeguard supplies, according to an announcement made today.
Activists stormed representatives of the French multinational pharmaceutical company Sanofi at the World Lung Health Conference. Organisations including the Treatment Action Campaign (TAC) have accused the company of profiteering and charging South Africans up to almost ten times the global price for a much needed medicine to treat drug-resistant tuberculosis (TB).
From your pet cat to the lions of the Kruger Park, animal carriers of tuberculosis (TB) are becoming an increasing concern as research continues to reveal TB in the most surprising of places.
More than 300 former tuberculosis (TB) patients, activists and health experts have demanded that countries like China, Brazil and India increase TB research funding as the bacteria continues to hundreds of thousands of their citizens in the ground each year.
More than 30,000 children develop tuberculosis (TB) each year in South Africa. For these children, cure comes in the form of six months of daily, bitter pills made for adults more than twice their size but new, better treatment may be on the way, according to research non-profit the TB Alliance.
Four South African research institutions are among the top 100 funders of tuberculosis (TB) research in the world according to a new report released today. If the country could triple TB research funding in the next three years, it could even outstrip richer countries.
No one knows how many South Africans are living with hepatitis C but the virus affects everyone from injecting drug users to suburban housewives. For decades, Hep C treatment was priced out of reach. Now, South Africa is importing new, better and cheaper drugs but a cure still comes at a cost.